Browse our inventory of complete processing plants available for purchase.
Browse our inventory of complete processing plants available for purchase.
Showing 2 of 2 matching plants. Search: "api".
190 Acre API Manufacturing Plant ComplexGrimsby, England, UK
This world-class, fully integrated API manufacturing site, formerly operated by Novartis, includes over 1,200m3 of total reactor vessel capacity across three distinct production buildings, available for sale or lease as a whole site or individual buildings for operation in-place. The facility could be utilized for pharmaceutical and animal health API manufacturing or repurposed for specialty/fine chemical manufacturing, flavors and fragrances, or agrochemicals.
Take the 360° Tour:
Building 110, Former Novartis Site, Grimsby
Building 150, Former Novartis Site, Grimsby
VIDEO: https://www.youtube.com/watch?v=AUWUHnAyWos&list=PLRlhdb05DXKR4eyHsLOkB6NzTyh2R4YCE
The site is located adjacent to the river Humber and between the Immingham and Grimsby port facilities, less than 5 minutes from downtown Grimsby, 25 minutes from Humberside Airport, 2.5 hours from Manchester Airport, 3.5 hours from London Heathrow.
Inside the fenceline is approximately 100 acres, with significant development land and infrastructure available inside the fence. There is an additional approximately 90 acres of agricultural land outside the fenceline.
Facility has the capabilities to perform various chemical synthesis, including hydrogenation, Grignard/Friedel-Crafts Reactions, Azide, and Tin Chemistries.
Building 110: Multi-product, Multi-purpose facility (ca. 1993)
Building 120: Mixed High Volume, Multi-Purpose Facility (ca. 1994/2007)
Building 150: High Volume, Multi-Product Facility (ca. 2004/2007)
Each building has its own dedicated solvent storage and recovery, in-process lab spaces, workshops, and offices.
Site Utilities:
The production buildings are supported by the following non-production infrastructure:
Warehousing:
The facility was not used in production of of plant/animal extracts, fermentation, penicilin, beta-lactams, steroids, hormonals, or cytoxic compounds.
A rare opportunity is now available to acquire a fully integrated petrochemical complex in Southeast Asia, designed for high-volume production of olefins and downstream polymers. This strategically located asset includes a world-scale naphtha cracker, aromatics production, and polymer plants—allowing buyers to enter or expand within the polyethylene (PE) and polypropylene (PP) markets with remarkable speed and significantly reduced capital cost.
For companies holding long naphtha feedstock positions or seeking immediate entry into ethylene, propylene, and polyethylene production, this facility offers a fast-track route to revenue generation:
| Segment | Capacity (t/yr) | | --- | --- | | Ethylene | 480,000 | | Propylene | 240,000 | | Butadiene | 70,000 | | Benzene | 90,000 | | Toluene | 50,000 | | Mixed Xylenes | 30,000 | This complex efficiently converts naphtha into high-value light olefins and aromatics, creating a competitive platform for polymer production and downstream chemicals.
| Polymer Plant | Capacity (t/yr) | | --- | --- | | Polypropylene (PP) | 300,000 | | Linear Low-Density PE (LLDPE) | 160,000 | | High-Density PE (HDPE) | 160,000 | | New PE Plant (commissioned ~July/Aug 2024, closing Feb 2025) | 250,000 | | Total PE Capacity | 570,000 |
The site is engineered to consume its own ethylene and propylene, feeding 570 kt of polyethylene and 300 kt of polypropylene—minimizing dependence on external feedstock and maximizing operating efficiency.
Unlike a greenfield build that requires years of permitting, engineering, construction, utilities development, workforce building, and commissioning—this asset already exists, operates, and is proven.
Producers supplying Asia-Pacific, India, Middle East, or export PE/PP global trade lanes can rapidly scale output and capture demand in fast-growing regions.
The site can be dismantled and relocated to your home country or industrial platform, preserving:
A relocation project can be:
Speed-to-market matters—this acquisition allows:
Confidential discussions are now open for: